CoChat
Sign Up
Cited by 1,061

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects

Begines, Belén, Ortiz, Tamara, Pérez-Aranda, María, Martínez, Guillermo, Merinero, Manuel, Argüelles-Arias, Federico, Alcudia, Ana·2020·Nanomaterials
DOI 10.3390/nano10071403PMC PMC7408012
Open this paper in CoChat — free account

Abstract

The complexity of some diseases—as well as the inherent toxicity of certain drugs—has led to an increasing interest in the development and optimization of drug-delivery systems. Polymeric nanoparticles stand out as a key tool to improve drug bioavailability or specific delivery at the site of action. The versatility of polymers makes them potentially ideal for fulfilling the requirements of each particular drug-delivery system. In this review, a summary of the state-of-the-art panorama of polymeric nanoparticles as drug-delivery systems has been conducted, focusing mainly on those applications in which the corresponding disease involves an important morbidity, a considerable reduction in the life quality of patients—or even a high mortality. A revision of the use of polymeric nanoparticles for ocular drug delivery, for cancer diagnosis and treatment, as well as nutraceutical delivery, was carried out, and a short discussion about future prospects of these systems is included.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nano10071403

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Classification of the different anatomic routes for drug delivery.
Figure 1 Classification of the different anatomic routes for drug delivery.CC BY · PubMed Central
Figure 2 Incidence rate of the most conventional eye diseases, according to the WHO (2019) [21].
Figure 2 Incidence rate of the most conventional eye diseases, according to the WHO (2019) [21].CC BY · PubMed Central
Figure 3 Schematic of the EPR effect: NPs pass through the endothelial fenestrations and reach cancer cells.
Figure 3 Schematic of the EPR effect: NPs pass through the endothelial fenestrations and reach cancer cells.CC BY · PubMed Central
Figure 4 Schematic of the active targeting process: NPs have been functionalized by adding ligands onto their surface that can recognize and bind the receptors in cancer cells.
Figure 4 Schematic of the active targeting process: NPs have been functionalized by adding ligands onto their surface that can recognize and bind the receptors in cancer cells.CC BY · PubMed Central
Figure 5 The exposure to a stimulus triggers congregated nanoparticles drug release.
Figure 5 The exposure to a stimulus triggers congregated nanoparticles drug release.CC BY · PubMed Central
Figure 6 Use of polymeric nanoparticles for nutraceuticals and different bioactive compounds for greater health and medical benefits.
Figure 6 Use of polymeric nanoparticles for nutraceuticals and different bioactive compounds for greater health and medical benefits.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 214

  1. Jain, 2020, An Overview of Drug Delivery Systems, Methods Mol. Biol., 2059, 1, 10.1007/978-1-4939-9798-5_1 · DOI
  2. Macedo, 2020, Novel and revisited approaches in nanoparticle systems for buccal drug delivery, J. Control. Release, 320, 125, 10.1016/j.jconrel.2020.01.006 · DOI
  3. Jain, 2020, Role of Nanobiotechnology in Drug Delivery, Methods Mol. Biol., 2059, 55, 10.1007/978-1-4939-9798-5_2 · DOI
  4. Chen, 2014, Advance of molecular imaging technology and targeted imaging agent in imaging and therapy, Biomed Res. Int., 2014, 1
  5. Essa, 2020, The Design of Poly (lactide-co-glycolide) Nanocarriers for Medical Applications, Front. Bioeng. Biotechnol., 8, 48, 10.3389/fbioe.2020.00048 · DOI
  6. Liu, 2018, One-Step Assembly of a Biomimetic Biopolymer Coating for Particle Surface Engineering, Adv. Mater., 30, e1802851, 10.1002/adma.201802851 · DOI
  7. Pla, 2016, Metal and Metal Oxide Nanoparticles: A Lever for C–H Functionalization, ACS Catal., 6, 3537, 10.1021/acscatal.6b00684 · DOI
  8. Begines, 2016, Synthesis of reduction sensitive comb-like polyurethanes using click chemistry, J. Polym. Sci. Part A Polym. Chem., 54, 3888, 10.1002/pola.28367 · DOI
  9. He, 2017, A Tripropylene Glycol Diacrylate-based Polymeric Support Ink for Material Jetting, Addit. Manuf., 16, 153
  10. Begines, 2013, Synthesis and Characterization of New Carbohydrate-based Polyureas, J. Renew. Mater., 1, 212, 10.7569/JRM.2013.634119 · DOI
  11. Begines, 2019, Design of highly stabilized nanocomposite inks based on biodegradable polymer-matrix and gold nanoparticles for Inkjet Printing, Sci. Rep., 9, 16097, 10.1038/s41598-019-52314-2 · DOI
  12. Nakama, Y. (2017). Surfactants. Cosmetic Science and Technology. Theoretical Principles and Applications, Elsevier. · DOI
  13. Zhao, 2019, Single-micelle-directed synthesis of mesoporous materials, Nat. Rev. Mater., 4, 775, 10.1038/s41578-019-0144-x · DOI
  14. Belletti, 2016, Exploiting The Versatility of Cholesterol in Nanoparticles Formulation, Int. J. Pharm., 511, 331, 10.1016/j.ijpharm.2016.07.022 · DOI
  15. Bonaccorso, 2018, Revisiting the role of sucrose in PLGA-PEG nanocarrier for potential intranasal delivery, Pharm. Dev. Technol., 23, 265, 10.1080/10837450.2017.1287731 · DOI
  16. Joseph, 2017, Investigations on pharmacokinetics and biodistribution of polymeric and solid lipid nanoparticulate systems of atypical antipsychotic drug: Effect of material used and surface modification, Drug Dev. Ind. Pharm., 43, 678, 10.1080/03639045.2016.1278014 · DOI
  17. Gao, 2016, Impact of surfactant treatment of paclitaxel nanocrystals on biodistribution and tumor accumulation in tumor-bearing mice, J. Control. Release, 237, 168, 10.1016/j.jconrel.2016.07.015 · DOI
  18. Chen, 2016, Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade, Cancer Lett., 370, 153, 10.1016/j.canlet.2015.10.010 · DOI
  19. Yin, 2018, Current Understanding of Interactions between Nanoparticles and ABC Transporters in Cancer Cells, Curr. Med. Chem., 25, 5930, 10.2174/0929867325666180314122200 · DOI
  20. Souto, E.B., Dias-Ferreira, J., López-Machado, A., Ettcheto, M., and Sánchez-López, E. (2019). Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents. Pharmaceutics, 11. · DOI
  21. Neumann, 2019, The gap between the need for novel retinal drug delivery methods, technologies in R&D phase, and approved ocular drug delivery technologies, Drug Discov. Today, 24, 1433, 10.1016/j.drudis.2019.03.018 · DOI
  22. Meng, 2019, Therapeutic implications of nanomedicine for ocular drug delivery, Drug Discov. Today, 24, 1524, 10.1016/j.drudis.2019.05.006 · DOI
  23. Gote, 2019, Ocular Drug Delivery: Present Innovations and Future Challenges, J. Pharmacol. Exp. Ther., 370, 602, 10.1124/jpet.119.256933 · DOI · Paper page
  24. Juliana, F.R., Kesse, S., Boakye-Yiadom, K.O., Veroniaina, H., Wang, H., and Sun, M. (2019). Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems. Molecules, 24. · DOI
  25. Blazaki, 2020, Novel Liposome Aggregate Platform (LAP) system for sustained retention of drugs in the posterior ocular segment following intravitreal injection, Int. J. Pharm., 576, 118987, 10.1016/j.ijpharm.2019.118987 · DOI
  26. Dukovski, 2020, Functional ibuprofen-loaded cationic nanoemulsion: Development and optimization for dry eye disease treatment, Int. J. Pharm., 576, 118979, 10.1016/j.ijpharm.2019.118979 · DOI
  27. Kim, 2014, Diamond Nanogel-Embedded Contact Lenses Mediate Lysozyme-Dependent Therapeutic Release, ACS Nano, 8, 2998, 10.1021/nn5002968 · DOI
  28. Romero, 2016, Development of cationic nanocrystals for ocular delivery, Eur. J. Pharm. Biopharm., 107, 215, 10.1016/j.ejpb.2016.07.005 · DOI
  29. Chi, 2017, Multifunctional organic–inorganic hybrid nanoparticles and nanosheets based on chitosan derivative and layered double hydroxide: Cellular uptake mechanism and application for topical ocular drug delivery, Int. J. Nanomed., 12, 1607, 10.2147/IJN.S129311 · DOI
  30. Park, 2019, Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation, J. Control. Release, 304, 125, 10.1016/j.jconrel.2019.05.003 · DOI
  31. Varshochian, 2015, Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment, J. Biomed. Mater. Res. A, 103A, 3148, 10.1002/jbm.a.35446 · DOI
  32. Ryu, W.M., Kim, S.-N., Min, C.H., and Choy, Y.B. (2019). Dry Tablet Formulation of PLGA Nanoparticles with a Preocular Applicator for Topical Drug Delivery to the Eye. Pharmaceutics, 11. · DOI
  33. Qiu, 2019, Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-RelatedMacular Degeneration, Molecualr Pharm., 16, 1958, 10.1021/acs.molpharmaceut.8b01319 · DOI
  34. Liu, 2019, Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles ForPotential Intravitreal Applications, Int. J. Nanomed., 14, 8819, 10.2147/IJN.S217038 · DOI
  35. Salama, 2017, PLGA Nanoparticles as Subconjunctival Injection for Management of Glaucoma, AAPS PharmSciTech, 18, 2517, 10.1208/s12249-017-0710-8 · DOI
  36. Pan, 2015, Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats, J. Control. Release, 201, 32, 10.1016/j.jconrel.2015.01.009 · DOI
  37. Li, 2012, Controlled Release of Bevacizumab through Nanospheres for Extended Treatment of Age-Related Macular Degeneration, Open Ophthalmol. J., 6, 54, 10.2174/1874364101206010054 · DOI
  38. Imam, 2018, Formulation and optimization of levofloxacin loaded chitosannanoparticle for ocular delivery: In-vitro characterization, oculartolerance and antibacterial activity, Int. J. Biol. Macromol., 108, 650, 10.1016/j.ijbiomac.2017.11.170 · DOI
  39. Badiee, 2018, Ocular implant containing bevacizumab-loaded chitosan nanoparticles intended for choroidal neovascularization treatment, J. Biomed. Mater. Res. A, 106, 2261, 10.1002/jbm.a.36424 · DOI
  40. Silva, M.M., Calado, R., Marto, J., Bettencourt, A., Almeida, A.J., and Gonçalves, L.M.D. (2017). Chitosan Nanoparticles as a Mucoadhesive Drug Delivery System for Ocular Administration. Mar. Drugs, 15. · DOI
  41. Hanafy, 2019, Ocular anti-inflammatory activity of prednisolone acetate loaded chitosan-deoxycholate self-assembled nanoparticles, Int. J. Nanomed., 14, 3679, 10.2147/IJN.S195892 · DOI
  42. Xu, X., Sun, L., Zhou, L., Cheng, Y., and Cao, F. (2020). Functional chitosan oligosaccharide nanomicelles for topical ocular drugdelivery of dexamethasone. Carbohydr. Polym., 227. · DOI · Paper page
  43. Shi, 2015, Chitosan grafted methoxy poly(ethylene glycol)-poly(e-caprolactone) nanosuspension for ocular delivery of hydrophobic diclofenac, Sci. Rep., 5, 11337, 10.1038/srep11337 · DOI
  44. Yu, 2019, Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: Formulation, in vitro and in vivo studies, Drug Deliv., 25, 888, 10.1080/10717544.2018.1458923 · DOI · Paper page
  45. Tang, 2019, Preparation and study of two kinds of ophthalmic nano-preparations of everolimus, Drug Deliv., 26, 1235, 10.1080/10717544.2019.1692966 · DOI
  46. Huang, 2018, Directing the nanoparticle formation by the combination with small molecular assembly and polymeric assembly for topical suppression of ocular inflammation, Int. J. Pharm., 551, 223, 10.1016/j.ijpharm.2018.09.015 · DOI
  47. Wen, 2018, A potential nanoparticle-loaded in situ gel for enhanced and sustained ophthalmic delivery of dexamethasone, Nanotechnology, 29, 425101, 10.1088/1361-6528/aad7da · DOI
  48. Hirani, 2016, Triamcinolone acetonide nanoparticles incorporated in thermoreversible gels for agerelated macular degeneration, Pharm. Dev. Technol., 21, 61, 10.3109/10837450.2014.965326 · DOI
  49. Yandrapu, 2012, Nanoparticles in Porous Microparticles Prepared by Supercritical Infusion and Pressure Quench Technology for Sustained Delivery of Bevacizumab, Mol. Pharm., 10, 4676, 10.1021/mp400487f · DOI
  50. Yang, 2019, A novel dendrimer-based complex co-modified with cyclic RGD hexapeptide and penetratin for noninvasive targeting and penetration of the ocular posterior segment, Drug Deliv., 26, 989, 10.1080/10717544.2019.1667455 · DOI
  51. Lancina, 2018, DenTimol as A Dendrimeric Timolol Analogue for Glaucoma Therapy: Synthesis and Preliminary Efficacy and Safety Assessment, Mol. Pharm., 15, 2883, 10.1021/acs.molpharmaceut.8b00401 · DOI
  52. Tai, 2017, A novel penetratin-modified complex for noninvasive intraocular delivery of antisense oligonucleotides, Int. J. Pharm., 529, 347, 10.1016/j.ijpharm.2017.06.090 · DOI
  53. Kambhampati, 2013, Dendrimer Nanoparticles for Ocular Drug Delivery, J. Ocul. Pharmacol. Ther., 29, 151, 10.1089/jop.2012.0232 · DOI
  54. Wu, 2014, Synthesis and evaluation of a nanoglobular dendrimer 5- aminosalicylic acid conjugate with a hydrolyzable chiff base spacer for treating retinal degeneration, ACS Nano, 8, 153, 10.1021/nn4054107 · DOI
  55. Spataro, 2010, Designing dendrimers for ocular drug delivery, Eur. J. Med. Chem., 45, 326, 10.1016/j.ejmech.2009.10.017 · DOI
  56. Tian, 2020, Cyclodextrin-based delivery systems for chemotherapeutic anticancer drugs: A review, Carbohydr. Polym., 232, 115805, 10.1016/j.carbpol.2019.115805 · DOI
  57. Guinchard, 2015, New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility and ocular tolerance, Eur. J. Pharm. Biopharm., 95, 203, 10.1016/j.ejpb.2015.04.032 · DOI
  58. Jansook, 2018, Cyclodextrin solubilization of celecoxib: Solid and solution state characterization, J. Incl. Phenom. Macrocycl. Chem., 90, 75, 10.1007/s10847-017-0769-6 · DOI
  59. Jansook, 2019, Development of celecoxib eye drop solution and microsuspension: A comparative investigation of binary and ternary cyclodextrin complexes, Carbohydr. Polym., 225, 115209, 10.1016/j.carbpol.2019.115209 · DOI
  60. Lorenzo-Veiga, B., Sigurdsson, H.H., Loftsson, T., and Alvarez-Lorenzo, C. (2019). Cyclodextrin-Amphiphilic Copolymer Supramolecular Assemblies for the Ocular Delivery of Natamycin. Nanomaterials, 9. · DOI
  61. Farace, 2016, Immune cell impact of three differently coated lipid nanocapsules: Pluronic, chitosan and polyethylene glycol, Sci. Rep., 6, 18423, 10.1038/srep18423 · DOI
  62. Zorzi, 2019, Box Behnken design of siRNA-loaded liposomes for the treatment of amurine model of ocular keratitis caused byAcanthamoeba, Colloids Surf. B Biointerfaces, 173, 725, 10.1016/j.colsurfb.2018.10.044 · DOI
  63. Patil, 2018, Formulation Development, Optimization, and In vitro—In vivo Characterization of Natamycin Loaded PEGylated Nano-lipid Carriers for Ocular Applications, J. Pharm. Sci., 107, 2160, 10.1016/j.xphs.2018.04.014 · DOI
  64. Mohammadhosseini, 2017, Magnetic nanoparticles in cancer diagnosis and treatment: A review, Artif. Cells Nanomed. Biotechnol., 45, 1, 10.3109/21691401.2016.1153483 · DOI
  65. Zhou, 2018, Magnetic particle imaging for radiation-free, sensitive and high-contrast vascular imaging and cell tracking, Curr. Opin. Chem. Biol., 45, 131, 10.1016/j.cbpa.2018.04.014 · DOI
  66. Wang, 2019, Optical, electrochemical and catalytic methods for in-vitro diagnosis using carbonaceous nanoparticles: A review, Microchim. Acta, 186, 50, 10.1007/s00604-018-3110-1 · DOI
  67. Thakor, 2013, Nanooncology: The future of cancer diagnosis and therapy, CA Cancer J. Clin., 63, 395, 10.3322/caac.21199 · DOI
  68. Maham, 2018, Gold Nanoparticles as X-Ray, CT, and Multimodal Imaging Contrast Agents: Formulation, Targeting, and Methodology, J. Nanomater., 2018, 5837276
  69. Kim, 2007, Antibiofouling Polymer-Coated Gold Nanoparticles as a Contrast Agent for in Vivo X-ray Computed Tomography Imaging, J. Am. Chem. Soc., 129, 7661, 10.1021/ja071471p · DOI
  70. Rabin, 2006, An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles, Nat. Mater., 5, 118, 10.1038/nmat1571 · DOI
  71. Joh, 2014, Gold-Loaded Polymeric Micelles for Computed Tomography-Guided Radiation Therapy Treatment and Radiosensitization, ACS Nano, 8, 104, 10.1021/nn405701q · DOI
  72. Lin, 2017, Doxorubicin-Loaded Unimolecular Micelle-Stabilized Gold Nanoparticles as a Theranostic Nanoplatform for Tumor-Targeted Chemotherapy and Computed Tomography Imaging, Biomacromolecules, 18, 3869, 10.1021/acs.biomac.7b00810 · DOI
  73. Park, 2018, Characterization and application of porous gold nanoparticles as 2-photon luminescence imaging agents: 20-fold brighter than gold nanorods, J. Biophotonics, 11, e201700174, 10.1002/jbio.201700174 · DOI
  74. Pearson, 2015, Intracellular accumulation and immunological properties of fluorescent gold nanoclusters in human dendritic cells, Biomaterials, 43, 1, 10.1016/j.biomaterials.2014.11.045 · DOI
  75. Wen, 2017, Spectral shape of one-photon luminescence from single gold nanorods, AIP Adv., 7, 125106, 10.1063/1.5008544 · DOI
  76. Wang, 2016, Biodegradable polymeric nanoparticles containing gold nanoparticles and Paclitaxel for cancer imaging and drug delivery using photoacoustic methods, Biomed. Opt. Express, 7, 4125, 10.1364/BOE.7.004125 · DOI
  77. Weissleder, 2006, Molecular Imaging in Cancer, Science, 312, 1168, 10.1126/science.1125949 · DOI
  78. Caravan, 2006, Strategies for increasing the sensitivity of gadolinium based MRI contrast agents, Chem. Soc. Rev., 35, 512, 10.1039/b510982p · DOI
  79. Chauhan, 2013, Strategies for advancing cancer nanomedicine, Nat. Mater., 12, 958, 10.1038/nmat3792 · DOI
  80. Choi, 2010, Design considerations for tumour-targeted nanoparticles, Nat. Nanotechnol., 5, 42, 10.1038/nnano.2009.314 · DOI · Paper page
  81. Ratzinger, 2010, Surface modification of PLGA nanospheres with Gd-DTPA and Gd-DOTA for high-relaxivity MRI contrast agents, Biomaterials, 31, 8716, 10.1016/j.biomaterials.2010.07.095 · DOI
  82. Caravan, P., and Zhang, Z. (2013). Targeted MRI Contrast Agents. Chem. Contrast Agents Med Magn. Reson. Imaging. · DOI
  83. Liu, 2011, Gadolinium-loaded polymeric nanoparticles modified with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer, Biomaterials, 32, 5167, 10.1016/j.biomaterials.2011.03.077 · DOI
  84. Esser, 2016, Gadolinium-functionalized nanoparticles for application as magnetic resonance imaging contrast agents via polymerization-induced self-assembly, Polym. Chem., 7, 7325, 10.1039/C6PY01797E · DOI
  85. Kim, 2010, Sentinel lymph nodes and lymphatic vessels: Noninvasive dual-modality in vivo mapping by using indocyanine green in rats—Volumetric spectroscopic photoacoustic imaging and planar fluorescence imaging, Radiology, 255, 442, 10.1148/radiol.10090281 · DOI
  86. Song, 2008, Noninvasive photoacoustic identification of sentinel lymph nodes containing methylene blue in vivo in a rat model, J. Biomed. Opt., 13, 054033, 10.1117/1.2976427 · DOI
  87. Li, 2012, Macromolecular Ligands for Gadolinium MRI Contrast Agents, Macromolecules, 45, 4196, 10.1021/ma300521c · DOI
  88. Zhang, 2008, Micelles based on biodegradable poly (L-glutamic acid)-b-polylactide with paramagnetic Gd ions chelated to the shell layer as a potential nanoscale MRI-visible delivery system, Biomacromolecules, 9, 36, 10.1021/bm700713p · DOI
  89. Hu, 2013, Synergistically Enhance Magnetic Resonance/Fluorescence Imaging Performance of Responsive Polymeric Nanoparticles under Mildly Acidic Biological Milieu, Macromol. Rapid Commun., 34, 749, 10.1002/marc.201200613 · DOI
  90. Li, 2012, Synthesis and In Vivo Pharmacokinetic Evaluation of Degradable Shell Cross-Linked Polymer Nanoparticles with Poly(carboxybetaine) versus Poly(ethylene glycol) Surface-Grafted Coatings, ACS Nano, 6, 8970, 10.1021/nn303030t · DOI
  91. Williams, 2001, In vivo studies of Gd-DTPA-monoclonal antibody and gd-porphyrins: Potential magnetic resonance imaging contrast agents for melanoma, J. Magn. Reson. Imaging, 14, 169, 10.1002/jmri.1168 · DOI
  92. Hu, 2017, Perylene Diimide-Grafted Polymeric Nanoparticles Chelated with Gd3+ for Photoacoustic/T1-Weighted Magnetic Resonance Imaging-Guided Photothermal Therapy, ACS Appl. Mater. Interfaces, 9, 30458, 10.1021/acsami.7b09633 · DOI
  93. Wu, 2018, Gadolinium-chelate functionalized bismuth nanotheranostic agent for in vivo MRI/CT/PAI imaging-guided photothermal cancer therapy, Biomaterials, 159, 37, 10.1016/j.biomaterials.2017.12.022 · DOI
  94. Barnett, 2011, Fluorine (19F) MRS and MRI in biomedicine, NMR Biomed., 24, 114, 10.1002/nbm.1570 · DOI
  95. Cyrus, 2005, Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy, Expert Rev. Cardiovasc. Ther., 3, 705, 10.1586/14779072.3.4.705 · DOI
  96. Knight, 2011, Fluorinated contrast agents for magnetic resonance imaging; a review of recent developments, RSC Adv., 1, 1415, 10.1039/c1ra00627d · DOI
  97. Wek, K.S. (2017). Development of Polymeric Therapeutic Nanoparticles: Toward Targeted Delivery and Efficient 19F MRI of Solid Tumors. [Ph.D. Thesis, Case Western Reserve University].
  98. Wallat, 2017, Optical and Magnetic Resonance Imaging Using Fluorous Colloidal Nanoparticles, Biomacromolecules, 18, 103, 10.1021/acs.biomac.6b01389 · DOI
  99. Pisani, 2006, Polymeric Nano/Microcapsules of Liquid Perfluorocarbons for Ultrasonic Imaging: Physical Characterization, Langmuir, 22, 4397, 10.1021/la0601455 · DOI
  100. Giraudeau, 2010, A new paradigm for high-sensitivity 19F magnetic resonance imaging of perfluorooctylbromide, Magn. Reson. Med., 63, 1119, 10.1002/mrm.22269 · DOI
  101. Diou, 2014, RGD decoration of PEGylated polyester nanocapsules of perfluorooctyl bromide for tumor imaging: Influence of pre or post-functionalization on capsule morphology, Eur. J. Pharm. Biopharm., 87, 170, 10.1016/j.ejpb.2013.12.003 · DOI
  102. Liopo, 2015, Melanin nanoparticles as a novel contrast agent for optoacoustic tomography, Photoacoustics, 3, 35, 10.1016/j.pacs.2015.02.001 · DOI
  103. Belletti, D., Riva, G., Luppi, M., Tosi, G., Forni, F., Vandelli, M., and Pederzoli, F. (2017). Anticancer drug-loaded quantum dots engineered polymeric nanoparticles: Diagnosis/therapy combined approach. Eur. J. Pharm. Sci., 107. · DOI
  104. Zhou, 2018, Targeted tumor dual mode CT/MR imaging using multifunctional polyethylenimine-entrapped gold nanoparticles loaded with gadolinium, Drug Deliv., 25, 178, 10.1080/10717544.2017.1422299 · DOI
  105. McQuade, 2015, A Multifunctional Nanoplatform for Imaging, Radiotherapy, and the Prediction of Therapeutic Response, Small, 11, 834, 10.1002/smll.201401927 · DOI
  106. Topete, 2014, Polymeric-Gold Nanohybrids for Combined Imaging and Cancer Therapy, Adv. Healthc. Mater., 3, 1309, 10.1002/adhm.201400023 · DOI
  107. Sun, 2007, Synthesis and characterization of biocompatible Fe3O4 nanoparticles, J. Biomed. Mater. Res. Part A, 80A, 333, 10.1002/jbm.a.30909 · DOI
  108. Qiao, 2009, Superparamagnetic iron oxide nanoparticles: From preparations to in vivo MRI applications, J. Mater. Chem., 19, 6274, 10.1039/b902394a · DOI · Paper page
  109. Fang, 2009, Multifunctional magnetic nanoparticles for medical imaging applications, J. Mater. Chem., 19, 6258, 10.1039/b902182e · DOI
  110. Zhao, 2019, Image-guided cancer therapy using aptamer-functionalized cross-linked magnetic-responsive Fe3O4@carbon nanoparticles, Anal. Chim. Acta, 1056, 108, 10.1016/j.aca.2018.12.045 · DOI
  111. Luo, 2015, RGD-functionalized ultrasmall iron oxide nanoparticles for targeted T1-weighted MR imaging of gliomas, Nanoscale, 7, 14538, 10.1039/C5NR04003E · DOI
  112. Franco, 2015, Long-circulating PEGylated manganese ferrite nanoparticles for MRI-based molecular imaging, Nanoscale, 7, 2050, 10.1039/C4NR05781C · DOI
  113. Calzoni, E., Cesaretti, A., Polchi, A., Di Michele, A., Tancini, B., and Emiliani, C. (2019). Biocompatible Polymer Nanoparticles for Drug Delivery Applications in Cancer and Neurodegenerative Disorder Therapies. J. Funct. Biomater., 10. · DOI
  114. Tran, S., DeGiovanni, P., Piel, B., and Rai, P. (2017). Cancer nanomedicine: A review of recent success in drug delivery. Clin. Trans. Med., 6. · DOI · Paper page
  115. Bregoli, 2016, Nanomedicine applied to translational oncology: A future perspective on cancer treatment, Nanomedicine, 12, 81, 10.1016/j.nano.2015.08.006 · DOI
  116. Priyamvada, P., Chandana, M., and Sahoo, S. (2012). Nanotechnology-based combinational drug delivery:an emerging approach for cancer therapy. Drug Discos. Today, 17. · DOI
  117. Cho, K., Wang, X.U., Nie, S., and Shin, D.M. (2008). Therapeutic Nanoparticles for Drug Delivery in Cancer. Clin. Cancer Res., 14. · DOI
  118. Senapati, 2018, Controlled drug delivery vehicles for cancer treatment and their performance, Signal Transduct. Target. Ther., 3, 7, 10.1038/s41392-017-0004-3 · DOI · Paper page
  119. Jiang, 2017, Influencing Selectivity to Cancer Cells with Mixed Nanoparticles Prepared from Albumin–Polymer Conjugates and Block Copolymers, Bioconjugate Chem., 28, 979, 10.1021/acs.bioconjchem.6b00698 · DOI
  120. Haley, 2008, Nanoparticles for drug delivery in cancer treatment, Urol. Oncol., 26, 57, 10.1016/j.urolonc.2007.03.015 · DOI
  121. Lamichhane, 2020, Albumin nanoscience: Homing nanotechnology enabling targeted drug delivery and therapy, Arch. Pharm. Res., 43, 118, 10.1007/s12272-020-01204-7 · DOI
  122. John, 2001, Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung, J. Physiol., 533, 547, 10.1111/j.1469-7793.2001.0547a.x · DOI
  123. Maeda, 2009, Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect, Eur. J. Pharm. Biopharm., 71, 409, 10.1016/j.ejpb.2008.11.010 · DOI
  124. Fang, 2011, The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect, Adv. Drug Deliv. Rev., 63, 136, 10.1016/j.addr.2010.04.009 · DOI
  125. Fang, J., Islam, R., Islam, W., Yin, H., Subr, V., Etrych, T., Ulbrich, K., and Maeda, H. (2019). Augmentation of EPR Effect and Efficacy of Anticancer Nanomedicine by Carbon Monoxide Generating Agents. Pharmaceutics, 11. · DOI
  126. Maeda, H. (2015). Toward a full understanding towards EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. · DOI · Paper page
  127. Pearce, 2019, Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine, Bioconjug. Chem., 30, 2300, 10.1021/acs.bioconjchem.9b00456 · DOI
  128. Ahmad, 2019, Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting, J. Med. Chem., 62, 10475, 10.1021/acs.jmedchem.9b00511 · DOI
  129. Ahmad, N., Ahmad, R., Alam, M.A., and Ahmad, F.J. (2018). Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. Chem. Cent. J., 12. · DOI
  130. Soma, 2002, Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles, Biomaterials, 21, 1, 10.1016/S0142-9612(99)00125-8 · DOI
  131. Zhao, 2019, An organic solvent-free technology for the fabrication of albumin-based paclitaxel nanoparticles for effective cancer therapy, Colloids Surf. B Biointerfaces, 183, 110394, 10.1016/j.colsurfb.2019.110394 · DOI
  132. Allard, 2011, Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model, Int. J. Pharm., 403, 201, 10.1016/j.ijpharm.2010.10.015 · DOI
  133. Guo, 2011, Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery, Biomaterials, 32, 8010, 10.1016/j.biomaterials.2011.07.004 · DOI
  134. Malinovskaya, 2017, Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells, Int. J. Pharm., 524, 77, 10.1016/j.ijpharm.2017.03.049 · DOI
  135. Hekmatara, 2009, Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects, Clin. Neuropathol., 28, 153, 10.5414/NPP28153 · DOI
  136. Khanna, 2019, Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer, Future Drug Discov., 1, FDD8, 10.4155/fdd-2019-0005 · DOI
  137. Yuan, J., ZhuGe, D., Tong, M., Lin, M., Xu, X., Tang, X., Zhao, Y., and Xu, H. (2018). pH-Sensitive polymeric nanoparticles of mPEG-PLGA-PGlu with hybrid core for simultaneous encapsulation of curcumin and doxorubicin to kill the heterogeneous tumour cells in breast cancer. Artif. Cells Nanomed. Biotechnol., 1–12. · DOI
  138. Hu, 2018, Oxygen-generating hybrid polymeric nanoparticles with encapsulated doxorubicin and chlorin e6 for trimodal imaging-guided combined chemo-photodynamic therapy, Theranostics, 8, 1558, 10.7150/thno.22989 · DOI
  139. Samadi, 2018, Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly (lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles, Pharm. Res., 35, 119, 10.1007/s11095-018-2404-7 · DOI
  140. Gao, 2019, Co-Delivery of Docetaxel and Salinomycin to Target Both Breast Cancer Cells and Stem Cells by PLGA/TPGS Nanoparticles, Int. J. Nanomed., 14, 9199, 10.2147/IJN.S230376 · DOI
  141. Li, 2018, Rational Design of Multifunctional Polymeric Nanoparticles Based on Poly(l-histidine) and d-α-Vitamin E Succinate for Reversing Tumor Multidrug Resistance, Biomacromolecules, 19, 2595, 10.1021/acs.biomac.8b00213 · DOI
  142. Zhu, 2016, Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer, Acta Biomater., 30, 144, 10.1016/j.actbio.2015.11.031 · DOI
  143. Hu, 2017, Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: In vitro and in vivo evaluation, Int. J. Pharm., 516, 313, 10.1016/j.ijpharm.2016.11.047 · DOI
  144. Jin, 2018, Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes, Int. J. Nanomed., 13, 2405, 10.2147/IJN.S161426 · DOI
  145. Tseng, 2018, Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting, Biomaterials, 28, 3996, 10.1016/j.biomaterials.2007.05.006 · DOI
  146. Tseng, 2008, Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer, Biomaterials, 29, 3014, 10.1016/j.biomaterials.2008.03.033 · DOI
  147. Tseng, 2009, The use of biotinylated-EGFmodified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation, Biomaterials, 30, 3476, 10.1016/j.biomaterials.2009.03.010 · DOI
  148. Choi, 2015, Inhalable self-assembled albumin nanoparticles for treating drug resistant lung cancer, J. Control. Release, 197, 199, 10.1016/j.jconrel.2014.11.008 · DOI
  149. Dong, 2012, Pulmonary delivery and tissue distribution of aerosolized antisense 2′-O-Methyl RNA containing nanoplexes in the isolated perfused and ventilated rat lung, Eur. J. Pharm. Biopharm., 81, 478, 10.1016/j.ejpb.2012.04.022 · DOI
  150. Nafee, 2012, Treatment of lung cancer via telomerase inhibition: Self-assembled nanoplexes versus polymeric nanoparticles as vectors for 2′-O-Methyl-RNA, Eur. J. Pharm. Biopharm., 80, 478, 10.1016/j.ejpb.2011.11.019 · DOI
  151. Azarmi, 2010, Secondary cytotoxicity mediated by alveolar macrophages: A contribution to the total efficacy of nanoparticles in lung cancer therapy?, Eur. J. Pharm. Biopharm., 76, 112, 10.1016/j.ejpb.2010.05.002 · DOI
  152. Zhong, 2016, Poly (amidoamine) Dendrimer-Doxorubicin Conjugates: In Vitro Characteristics and Pseudosolution Formulation in Pressurized Metered-Dose Inhalers, Mol. Pharm., 13, 1058, 10.1021/acs.molpharmaceut.5b00876 · DOI
  153. Xie, 2010, Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer, Int. J. Pharm., 392, 156, 10.1016/j.ijpharm.2010.03.058 · DOI
  154. Gautam, 2002, Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis, Cancer Gene Ther., 9, 28, 10.1038/sj.cgt.7700405 · DOI
  155. Hong, 2015, Dual expression of shAkt1 and Pdcd4 suppresses lung tumorigenesis in K-rasLA1 mice, Anticancer Res., 35, 2015
  156. Kim, 2004, Aerosol delivery of glucosylated polyethylenimine/phosphatase and tensin homologue deleted on chromosome 10 complex suppresses Akt downstream pathways in the lung of K-ras null mice, Cancer Res., 64, 7971, 10.1158/0008-5472.CAN-04-1231 · DOI
  157. Jin, 2006, Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice, Mol. Cancer Ther., 5, 1041, 10.1158/1535-7163.MCT-05-0433 · DOI
  158. Jin, 2008, Urocanic acid-modified chitosan-mediated PTEN delivery via aerosol suppressed lung tumorigenesis in K-ras(LA1) mice, Cancer Gene Ther., 15, 275, 10.1038/sj.cgt.7701116 · DOI
  159. Jiang, 2011, Aerosol delivery of spermine-based poly(amino ester)/Akt1 shRNA complexes for lung cancer gene therapy, Int. J. Pharm., 420, 256, 10.1016/j.ijpharm.2011.08.045 · DOI
  160. Kim, 2014, Spermine-alt-poly(ethylene glycol) polyspermine as a safe and efficient aerosol gene carrier for lung cancer therapy, J. Biomed. Mater Res. A, 102, 2230, 10.1002/jbm.a.34905 · DOI
  161. Jiang, 2007, Chitosan-graft-polyethylenimine as a gene carrier, J. Control. Release, 117, 273, 10.1016/j.jconrel.2006.10.025 · DOI
  162. Jiang, 2009, The suppression of lung tumorigenesis by aerosol-delivered folate-chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway, Biomaterials, 30, 5844, 10.1016/j.biomaterials.2009.07.017 · DOI
  163. Zou, 2007, p53 Aerosol formulation with low toxicity and high efficiency for early lung cancer treatment, Clin. Cancer Res., 13, 4900, 10.1158/1078-0432.CCR-07-0395 · DOI
  164. Xu, 2008, Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis, Am. J. Respir. Crit. Care Med., 178, 60, 10.1164/rccm.200707-1022OC · DOI
  165. Xu, 2015, Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer, Small, 11, 4321, 10.1002/smll.201501034 · DOI
  166. Xu, 2015, A pH sensitive co-delivery system of siRNA and doxorubicin for pulmonary administration to B16F10 metastatic lung cancer, RSC Adv., 5, 103380, 10.1039/C5RA21934E · DOI
  167. Lin, 2015, Smart polymeric nanoparticles for cancer gene delivery, Mol. Pharm., 12, 314, 10.1021/mp500656v · DOI
  168. Santini, 2018, Nutraceuticals: Opening the debate for a regulatory framework, Br. J. Clin. Pharmacol., 84, 659, 10.1111/bcp.13496 · DOI
  169. Aronson, 2017, Defining ‘nutraceuticals’: Neither nutritious nor pharmaceutical, Br. J. Clin. Pharmacol., 83, 8, 10.1111/bcp.12935 · DOI
  170. Rajapakse, 2016, Nutraceuticals in Migraine: A Summary of Existing Guidelines for Use, Headache, 56, 808, 10.1111/head.12789 · DOI
  171. Santini, 2017, Nutraceuticals in hypercholesterolaemia: An overview, Br. J. Clin. Pharmacol., 174, 1450, 10.1111/bph.13636 · DOI
  172. Rivellese, 2019, The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease, High Blood Press. Cardiovasc. Prev. Off. J. Ital. Soc. Hypertens., 26, 101, 10.1007/s40292-019-00309-5 · DOI
  173. Poli, 2019, Pharmacology of Nutraceuticals with Lipid Lowering Properties, High Blood Press. Cardiovasc. Prev. Off. J. Ital. Soc. Hypertens., 26, 113, 10.1007/s40292-019-00311-x · DOI
  174. Borghi, 2017, Nutraceuticals with a clinically detectable blood pressure-lowering effect: A review of available randomized clinical trials and their meta-analyses, Br. J. Clin. Pharmacol., 83, 163, 10.1111/bcp.12902 · DOI
  175. Brown, 2019, Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: Systematic review and meta-analysis of randomised controlled trials, BMJ, 366, l4697, 10.1136/bmj.l4697 · DOI · Paper page
  176. Jovanovski, 2019, Should Viscous Fiber Supplements Be Considered in Diabetes Control? Results from a Systematic Review and Meta-analysis of Randomized Controlled Trials, Diabetes Care, 42, 755, 10.2337/dc18-1126 · DOI
  177. Varela-López, A., Navarro-Hortal, M.D., Giampieri, F., Bullón, P., Battino, M., and Quiles, J.L. (2018). Nutraceuticals in Periodontal Health: A Systematic Review on the Role of Vitamins in Periodontal Health Maintenance. Molecules, 23. · DOI
  178. Orr, 2018, The Evidence for the Role of Nutraceuticals in the Management of Pediatric Migraine: A Review, Curr. Pain Headache Rep., 22, 37, 10.1007/s11916-018-0692-6 · DOI
  179. Wang, 2018, Nutraceuticals and osteoarthritis pain, Pharmacol. Ther., 187, 167, 10.1016/j.pharmthera.2018.02.015 · DOI
  180. Jones, 2019, Bioavailability of nanotechnology-based bioactives and nutraceuticals, Adv. Food Nutr. Res., 88, 235, 10.1016/bs.afnr.2019.02.014 · DOI
  181. Liu, 2016, Research progress on berberine with a special focus on its oral bioavailability, Fitoterapia, 109, 274, 10.1016/j.fitote.2016.02.001 · DOI · Paper page
  182. Sharma, 2004, Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 10, 6847, 10.1158/1078-0432.CCR-04-0744 · DOI
  183. Pollack, 2017, Resveratrol Improves Vascular Function and Mitochondrial Number but Not Glucose Metabolism in Older Adults, J. Gerontol. Ser. A Biol. Sci. Med Sci., 72, 1703, 10.1093/gerona/glx041 · DOI
  184. Fan, 2013, Enhancement by sodium caprate and sodium deoxycholate of the gastrointestinal absorption of berberine chloride in rats, Drug Dev. Ind. Pharm., 39, 1447, 10.3109/03639045.2012.723219 · DOI
  185. Piskula, M.K., Murota, K., and Terao, J. (2012). Bioavailability of flavonols and flavones. Flavonoids and Related Compounds: Bioavailability and Function, CRC Press. · DOI
  186. Rich, G.T., Buchweitz, M., Winterbone, M.S., Kroon, P.A., and Wilde, P.J. (2017). Towards an Understanding of the Low Bioavailability of Quercetin: A Study of Its Interaction with Intestinal Lipids. Nutrients, 9. · DOI
  187. Hisanaga, 2016, Anti-inflammatory effects and molecular mechanisms of 8-prenyl quercetin, Mol. Nutr. Food Res., 60, 1020, 10.1002/mnfr.201500871 · DOI
  188. Barahona, 2019, Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders, Future Med. Chem., 11, 847, 10.4155/fmc-2018-0313 · DOI
  189. Schiborr, 2018, The Oral Bioavailability of Trans-Resveratrol from a Grapevine-Shoot Extract in Healthy Humans is Significantly Increased by Micellar Solubilization, Mol. Nutr. Food Res., 62, e1701057, 10.1002/mnfr.201701057 · DOI
  190. Xiong, 2018, Enhancing the photostability and bioaccessibility of resveratrol using ovalbumin-carboxymethylcellulose nanocomplexes and nanoparticles, Food Funct., 9, 3788, 10.1039/C8FO00300A · DOI
  191. Jaisamut, 2017, A Novel Self-Microemulsifying System for the Simultaneous Delivery and Enhanced Oral Absorption of Curcumin and Resveratrol, Planta Med., 83, 461
  192. Yadav, 2018, Enhancement of anticancer activity and drug delivery of chitosan-curcumin nanoparticle via molecular docking and simulation analysis, Carbohydr. Polym., 182, 188, 10.1016/j.carbpol.2017.10.102 · DOI
  193. Jaiswal, 2018, Co-delivery of curcumin and serratiopeptidase in HeLa and MCF-7 cells through nanoparticles show improved anti-cancer activity, Mater. Sci. Eng. C Mater. Biol. Appl., 92, 673, 10.1016/j.msec.2018.07.025 · DOI
  194. Liu, 2018, Co-Delivery of Triptolide and Curcumin for Ovarian Cancer Targeting Therapy via mPEG-DPPE/CaP Nanoparticle, J. Biomed. Nanotechnol., 14, 1761, 10.1166/jbn.2018.2633 · DOI
  195. Xiao, 2016, Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation, Theranostics, 6, 2250, 10.7150/thno.15710 · DOI
  196. Gugulothu, 2014, pH-sensitive nanoparticles of curcumin-celecoxib combination: Evaluating drug synergy in ulcerative colitis model, J. Pharm. Sci., 103, 687, 10.1002/jps.23828 · DOI
  197. Niazvand, 2017, Curcumin-loaded poly lactic-co-glycolic acid nanoparticles effects on mono-iodoacetate -induced osteoarthritis in rats, Vet. Res. Forum Int. Q. J., 8, 155
  198. Ohno, M., Nishida, A., Sugitani, Y., Nishino, K., Inatomi, O., Sugimoto, M., Kawahara, M., and Andoh, A. (2017). Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells. PLoS ONE, 12. · DOI
  199. Natesan, 2017, Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction, Int. J. Biol. Macromol., 104, 1837, 10.1016/j.ijbiomac.2017.04.117 · DOI
  200. Song, 2018, Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid-polymer hybrid nanoparticles, Biomed. Pharmacother., 105, 18, 10.1016/j.biopha.2018.05.095 · DOI

200 of 214 shown

Cited by

Sorted by citations

See all 1,061

Metadata

Authors
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A.
Venue
Nanomaterials
Publisher
MDPI AG
Published
2020-07-19
Volume
10
Issue
7
Pages
1403
ISSN
2079-4991
DOI
10.3390/nano10071403
PMC
PMC7408012
Cited by
1,061
References
4
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review